Cardima
This article was originally published in The Gray Sheet
Executive Summary
Second tranche of a $15 mil. private placement is complete. The sale of approximately 1.7 mil. shares at $2 each follows the Jan. 21 placement of about 5.8 mil. shares at the same price. The proceeds, in conjunction with a 30% company-wide reduction in workforce, will facilitate the continuing European roll-out of the Revelation and Revelation Tx microcatheters for therapeutic treatment of atrial fibrillation. An ongoing U.S. AF trial also will be expanded
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.